Fundraising Fox

Dina Chaya

Investor

Partner at OrbiMed · Board director at Spruce Biosciences

London

Writes $100K – $5M checks · typically $1.5M

Find your path to Dina

2,024 people in our graph share verified history with Dina — schools, employers, funds. One of them is your warm intro.

Niko BonatsosunlockedDina: together at University of Cambridge
×11Dina: together at Index Ventures

About

Dina Chaya is a Partner on the Private Equity team at OrbiMed, with healthcare investment experience in Europe and the US since 2001 across private equity and venture capital. Her prior roles include positions at Omega Funds, NeoMed Management, 3i Group, and Index Ventures, and her portfolio includes investments in companies acquired by Merck, AstraZeneca, Alexion Pharmaceuticals, and Jazz Pharmaceuticals. Chaya holds a CFA charter and a Ph.D. in Molecular and Cellular Biology from Paris VI University, with postdoctoral research experience at Brown University and Fox Chase Cancer Centre.

Board director at Spruce Biosciences

Intro paths

→

In turn, Dina can intro founders to Spruce Biosciences's investors below.

Spruce Biosciences's investors · 6

AbingworthLondon · $15M – $30M checks · since 2025Aisling CapitalNew YorkHealthCapStockholm · since 2020Norwest Venture PartnersMenlo Park · $10M – $30M checks · since 2025OrbiMedNew York · $1M – $75M checks · since 2020RiverVest Venture PartnersSt. Louis · $500K – $3M checks · since 2020

Experience

  1. OrbiMedPartnercurrent2023 — presentLondon, United Kingdom
  2. Monks Investment Trust PLCBoard Director2022 — 2025
  3. Omega FundsPartner2017 — 2023
  4. NeoMedPartner2009 — 2023
  5. Invest EuropeMember of the Venture Capital Platform Council2018 — 2022
  6. 3i Group plcDirector Growth Capital / Venture Capital2004 — 2008
  7. Index VenturesAssociate2001 — 2004
  8. Fox Chase Cancer CenterPostdoctoral Fellow2000 — 2001
  9. Brown UniversityPostdoctoral Fellow1998 — 2000

Skills & more

Venture Capital29Private Equity22Start-ups14Investments12Pharmaceutical Industry3Growth Capital6Medical Devices6Due Diligence7Corporate Development13Valuation3MergersFunding3
+3 moreEntrepreneurshipBusiness StrategyInvestment Banking

From Dina's professional profile.

Deals · 1

Spruce BiosciencesBoard seat

via OrbiMed · filed Feb 2023 · $53.6M raise

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at OrbiMed

Aldo Brambilla
Associate at Silver Lake Partners
Alexander M. Cooper
Investor at OrbiMed
Anat Naschitz
Executive Officer at OrbiMed
Anat Nursella
Venture Partner at OrbiMed
Andrew P. Kanarek, CFA, CIPM
Investor at OrbiMed
Ankesh Bhansali
Investor at OrbiMed
Arun Sadhanandham
Investor at OrbiMed
Ava Poole
Investor at Insight Partners

Network3

Anat Nursella
Venture Partner at OrbiMed
Brendan Weber
Principal at OrbiMed
Charles Steinman
Analyst at OrbiMed

Investors connected to Dina in public investor directories — a warm-intro map.

Frequently asked questions

Who is Dina Chaya?
Dina Chaya is a Partner on the Private Equity team at OrbiMed, with healthcare investment experience in Europe and the US since 2001 across private equity and venture capital. Her prior roles include positions at Omega Funds, NeoMed Management, 3i Group, and Index Ventures, and her portfolio includes investments in companies acquired by Merck, AstraZeneca, Alexion Pharmaceuticals, and Jazz Pharmaceuticals. Chaya holds a CFA charter and a Ph.D. in Molecular and Cellular Biology from Paris VI University, with postdoctoral research experience at Brown University and Fox Chase Cancer Centre.
Where does Dina Chaya work?
Dina Chaya is Partner at OrbiMed and Board director at Spruce Biosciences.
What check size does Dina Chaya write?
Dina Chaya typically writes checks of $100K – $5M.
What boards does Dina Chaya sit on?
Dina Chaya holds tracked board seats at Spruce Biosciences.
Where did Dina Chaya go to school?
Dina Chaya studied at CFA Institute (Chartered Financial Analyst Degree, Finance); Pierre and Marie Curie University (PhD, Molecular & Cellular Biology of Development); Pierre and Marie Curie University (DEA, Molecular & Cellular Biology of Development).

Same school

Also attended Pierre and Marie Curie University85

Guillaume LampleCo-founder & Chief Scientist of Mistral AIThomas WolfCo-founder & Chief Science Officer of Hugging FaceJeff ClavierFounding Partner at Uncork CapitalJean SiniGeneral Partner at Partech VenturesDimitri KrempPrincipal at Axeleo CapitalJack GuedjInvestor at Sand Hill Angels

+ 79 more

Also attended University of Cambridge1,403

Stewart ButterfieldCo-founder of Slack and FlickrDemis HassabisCo-founder & CEO of Google DeepMindNiko BonatsosFounder and Managing Partner of VerdictGeorgia StevensonInvestor at Index VenturesHannah SealInvestor at Index VenturesLeah von SiemensPartner at Manta Ray Ventures

+ 1,397 more

Shared employers

Also worked at Omega Funds21

Nessan BerminghamInvestor at Khosla VenturesLiam FlahertyInvestor at Silversmith Capital PartnersRichard LimManaging Partner at Cure VenturesAnnie MitsakPartner at Cure VenturesJohn MaraganoreAdvisor at Oak HC/FTWalter StockingerManaging Partner at Hadean Ventures

+ 15 more

Also worked at 3i Group plc144

Sean BrownleePartner at Rho VenturesGiuseppe DonvitoPartner at P101 VenturesMarco FumagalliBoard Member at P101 VenturesAndrea ScholzSenior Executive Assistant at Sapphire VenturesJan-Olivier FillolsSenior Managing Director at Marlin Equity PartnersJeremy NakacheManaging Director at Marlin Equity Partners

+ 138 more

Also worked at Index Ventures130

Danny RimerPartner at Index VenturesAdrianna MaInvestor at Index VenturesAli Fisher SweetInvestor at Index VenturesAna AndreescuInvestor at Index VenturesAndré DuboisInvestor at Index VenturesAvron MarcusInvestor at Index Ventures

+ 124 more

Also worked at Fox Chase Cancer Center2

Ricardo SalomãoManaging Partner at Green RockMark FeitelsonFounder at SFA Therapeutics